CellCarta and Imagene AI Expanded Diagnostics Partnership
The collaboration links AI-driven biomarker prediction with laboratory infrastructure to support clinical diagnostic development.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Should artificial intelligence be more widely used to develop new medical diagnostic tests?
CellCarta and Imagene AI have formally expanded their collaboration to integrate AI-powered biomarker discovery into companion diagnostic development programs. This initiative currently supports active clinical programs for two global pharmaceutical firms.
Why it matters
Pharmaceutical developers require established pathways to move AI-derived biomarker insights from research into validated clinical assays. This partnership combines technical biomarker capabilities with the regulatory and clinical infrastructure necessary to execute these programs at scale.
The partnership includes the development of an AI-powered IHC (immunohistochemistry) companion diagnostic and an application of Imagene AI’s Lung Prediction Panel in non-small cell lung cancer. This panel utilizes H&E (hematoxylin and eosin) stained whole-slide images to predict biomarkers, though the technology remains classified as Research Use Only.
The players
CellCarta
A global laboratory services organization that provides specialized services in clinical trial deployment, molecular pathology, and regulatory compliance.
Imagene AI
A developer of artificial intelligence technologies that analyze standard pathological images to predict tissue biomarkers.
The details
Imagene AI contributes proprietary algorithms that analyze H&E images—standard tissue slides stained with two common dyes—to identify biomarker patterns without requiring additional staining. CellCarta provides the necessary laboratory infrastructure, including clinical trial deployment and regulatory support, to transition these AI capabilities into regulated diagnostics. This pipeline covers the full development lifecycle, from initial biomarker strategy to final regulatory submission.
Timeline
October 2, 2026: The partnership expansion was formally announced.
The Tech Race
The move follows a broader industry race to standardize AI-based diagnostics within the regulated pharmaceutical pipeline. This collaboration aims to bridge the gap between early-stage biomarker research and the clinical validation required for widespread diagnostic adoption.
This collaboration focuses on internal pharmaceutical research workflows, meaning it does not currently change clinical diagnostics available to patients. The use of the Lung Prediction Panel remains restricted to Research Use Only as the companies continue their clinical trial integration.
The takeaway
The partnership highlights the critical hurdle of translating AI biomarker models into actionable, regulatory-ready diagnostic assays. Industry stakeholders should watch for upcoming clinical trial results and subsequent regulatory filings for the new IHC-based diagnostics currently in development.
Further reading
For more on the latest in diagnostic innovation, see our full coverage of Biotech.
Source note: This article includes information reported by Selectscience.
Live Poll
Should artificial intelligence be more widely used to develop new medical diagnostic tests?
